Schistosomiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major schistosomiasis markets reached a value of US$ 52.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 71.4 Million by 2034, exhibiting a growth rate (CAGR) of 2.92% during 2024-2034.
The schistosomiasis market has been comprehensively analyzed in IMARC's new report titled "Schistosomiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schistosomiasis, also referred to as bilharzia, is a parasitic ailment caused by infection with blood fluke worms of the genus Schistosoma. In the early acute stage, patients may experience fever, chills, headaches, muscle aches, and a skin rash known as "swimmer's itch" from the penetration of cercariae into the skin. As the condition progresses to the chronic stage, symptoms may include diarrhea, abdominal pain, blood in the urine or stool, liver and spleen enlargement, fatigue, etc. In cases of urogenital schistosomiasis, there can be bladder and urinary tract complications, such as painful urination and an increased likelihood of urinary tract infections. During the clinical evaluation, healthcare providers inquire about symptoms, exposure to freshwater sources, and travel history to endemic regions. Numerous laboratory procedures, including the examination of stool or urine samples for the presence of parasite eggs using microscopic techniques, are performed. For more sensitive and specific diagnostics, rapid diagnostic tests (RDTs) that detect schistosome antigens in blood or urine are increasingly used. In cases of suspected organ involvement, various imaging studies, including ultrasound or computed tomography (CT) scans, help in revealing evidence of tissue damage or enlargement of organs.
The increasing cases of contact with contaminated water, through which the parasitic worms penetrate the skin and enter the bloodstream, initiating the infection, are primarily driving the schistosomiasis market. Furthermore, the inflating application of praziquantel that works by paralyzing and killing the adult worms, which are then expelled from the body through urine or feces, is creating a positive outlook for the market. Apart from this, the widespread adoption of host-directed therapies, since they aid in minimizing inflammation and tissue damage caused by the parasite, thus reducing the symptoms associated with the condition and improving treatment outcomes, is also bolstering the market growth. Moreover, various key players are making extensive investments in R&D activities to introduce vaccines that target several schistosome antigens to stimulate protective immune responses and alleviate reinfection rates, thereby potentially limiting disease severity. This, in turn, is further acting as another significant growth-inducing factor. Additionally, the ongoing advancements in diagnostic technologies, such as the introduction of loop-mediated isothermal amplification (LAMP), that can detect low parasite loads with high sensitivity and offer improved accuracy, are expected to drive the schistosomiasis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the schistosomiasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schistosomiasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schistosomiasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the schistosomiasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the schistosomiasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current schistosomiasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the schistosomiasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the schistosomiasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the schistosomiasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of schistosomiasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of schistosomiasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of schistosomiasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with schistosomiasis across the seven major markets?
What is the size of the schistosomiasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of schistosomiasis?
What will be the growth rate of patients across the seven major markets?
Schistosomiasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for schistosomiasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schistosomiasis market?
What are the key regulatory events related to the schistosomiasis market?
What is the structure of clinical trial landscape by status related to the schistosomiasis market?
What is the structure of clinical trial landscape by phase related to the schistosomiasis market?
What is the structure of clinical trial landscape by route of administration related to the schistosomiasis market?
The schistosomiasis market has been comprehensively analyzed in IMARC's new report titled "Schistosomiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Schistosomiasis, also referred to as bilharzia, is a parasitic ailment caused by infection with blood fluke worms of the genus Schistosoma. In the early acute stage, patients may experience fever, chills, headaches, muscle aches, and a skin rash known as "swimmer's itch" from the penetration of cercariae into the skin. As the condition progresses to the chronic stage, symptoms may include diarrhea, abdominal pain, blood in the urine or stool, liver and spleen enlargement, fatigue, etc. In cases of urogenital schistosomiasis, there can be bladder and urinary tract complications, such as painful urination and an increased likelihood of urinary tract infections. During the clinical evaluation, healthcare providers inquire about symptoms, exposure to freshwater sources, and travel history to endemic regions. Numerous laboratory procedures, including the examination of stool or urine samples for the presence of parasite eggs using microscopic techniques, are performed. For more sensitive and specific diagnostics, rapid diagnostic tests (RDTs) that detect schistosome antigens in blood or urine are increasingly used. In cases of suspected organ involvement, various imaging studies, including ultrasound or computed tomography (CT) scans, help in revealing evidence of tissue damage or enlargement of organs.
The increasing cases of contact with contaminated water, through which the parasitic worms penetrate the skin and enter the bloodstream, initiating the infection, are primarily driving the schistosomiasis market. Furthermore, the inflating application of praziquantel that works by paralyzing and killing the adult worms, which are then expelled from the body through urine or feces, is creating a positive outlook for the market. Apart from this, the widespread adoption of host-directed therapies, since they aid in minimizing inflammation and tissue damage caused by the parasite, thus reducing the symptoms associated with the condition and improving treatment outcomes, is also bolstering the market growth. Moreover, various key players are making extensive investments in R&D activities to introduce vaccines that target several schistosome antigens to stimulate protective immune responses and alleviate reinfection rates, thereby potentially limiting disease severity. This, in turn, is further acting as another significant growth-inducing factor. Additionally, the ongoing advancements in diagnostic technologies, such as the introduction of loop-mediated isothermal amplification (LAMP), that can detect low parasite loads with high sensitivity and offer improved accuracy, are expected to drive the schistosomiasis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the schistosomiasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for schistosomiasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the schistosomiasis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the schistosomiasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the schistosomiasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current schistosomiasis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the schistosomiasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the schistosomiasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the schistosomiasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of schistosomiasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of schistosomiasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of schistosomiasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with schistosomiasis across the seven major markets?
What is the size of the schistosomiasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of schistosomiasis?
What will be the growth rate of patients across the seven major markets?
Schistosomiasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for schistosomiasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the schistosomiasis market?
What are the key regulatory events related to the schistosomiasis market?
What is the structure of clinical trial landscape by status related to the schistosomiasis market?
What is the structure of clinical trial landscape by phase related to the schistosomiasis market?
What is the structure of clinical trial landscape by route of administration related to the schistosomiasis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SCHISTOSOMIASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SCHISTOSOMIASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SCHISTOSOMIASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SCHISTOSOMIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SCHISTOSOMIASIS - UNMET NEEDS
10 SCHISTOSOMIASIS - KEY ENDPOINTS OF TREATMENT
11 SCHISTOSOMIASIS - MARKETED PRODUCTS
11.1 List of Schistosomiasis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 SCHISTOSOMIASIS - PIPELINE DRUGS
12.1 List of Schistosomiasis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. SCHISTOSOMIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SCHISTOSOMIASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SCHISTOSOMIASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Schistosomiasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Schistosomiasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Schistosomiasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Schistosomiasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Schistosomiasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Schistosomiasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Schistosomiasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Schistosomiasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Schistosomiasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Schistosomiasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Schistosomiasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Schistosomiasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Schistosomiasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Schistosomiasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Schistosomiasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Schistosomiasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Schistosomiasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Schistosomiasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Schistosomiasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Schistosomiasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Schistosomiasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Schistosomiasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Schistosomiasis - Access and Reimbursement Overview
16 SCHISTOSOMIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SCHISTOSOMIASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SCHISTOSOMIASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SCHISTOSOMIASIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SCHISTOSOMIASIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SCHISTOSOMIASIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SCHISTOSOMIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SCHISTOSOMIASIS - UNMET NEEDS
10 SCHISTOSOMIASIS - KEY ENDPOINTS OF TREATMENT
11 SCHISTOSOMIASIS - MARKETED PRODUCTS
11.1 List of Schistosomiasis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 SCHISTOSOMIASIS - PIPELINE DRUGS
12.1 List of Schistosomiasis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. SCHISTOSOMIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SCHISTOSOMIASIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SCHISTOSOMIASIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Schistosomiasis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Schistosomiasis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Schistosomiasis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Schistosomiasis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Schistosomiasis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Schistosomiasis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Schistosomiasis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Schistosomiasis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Schistosomiasis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Schistosomiasis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Schistosomiasis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Schistosomiasis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Schistosomiasis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Schistosomiasis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Schistosomiasis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Schistosomiasis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Schistosomiasis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Schistosomiasis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Schistosomiasis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Schistosomiasis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Schistosomiasis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Schistosomiasis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Schistosomiasis - Access and Reimbursement Overview
16 SCHISTOSOMIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SCHISTOSOMIASIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SCHISTOSOMIASIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
